Health TrialsbyHealthPanel

Interaction Between White Potato Consumption and Meal Timing on Glycemic Response and Appetite in Adults

ConditionsHealthyAdultAppetiteGlycemic ResponseMealtiming
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-65
SponsorToronto Metropolitan University

About this trial

The purpose of this study is to evaluate the interaction between white potato consumption and meal timing on glycemic response, subjective appetite, and energy intake in adults. The investigators hypothesize that white potatoes will modulate glycemic response, enhance satiety, and mitigate subsequent meal consumption and overall food intake when compared with meals containing low glycemic carbohydrates. Furthermore, they anticipate that the timing of white potato consumption will yield differential effects, with breakfast consumption exerting a more pronounced impact on satiety and subsequent food intake reduction compared to dinner consumption.

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

18 - 65 years

within the healthy body weight range [body mass index (BMI) between 18.5 - 24.9 kg/m2].

Disqualifiers

have a previous diagnosis of diabetes and gastrointestinal, liver or kidney disease;

have had a major medical or surgical event within the past 6 months;

have had any significant weight fluctuation in the past 6-months;

are taking medication that may influence dependent measures;

Trial design

Design model

Crossover

Treatments tested in this trial

  • Oven-baked Home Fries

    Other intervention

    Oven-baked Home Fries (241 g; McCain Ltd.). Test treatments matched for calories (284 kcal)

  • Oven-baked White Russet Potato

    Other intervention

    Oven-baked White Russet Potato (299 g). Test treatments matched for calories (284 kcal)

  • Oven-baked Fries

    Other intervention

    Oven-baked Fries (201 g; McCain Ltd.). Test treatments matched for calories (284 kcal)

  • Deep Fried, Quick Serve Fries

    Other intervention

    Deep Fried, Quick Serve Fries (108 g; McCain Ltd.). Test treatments matched for calories (284 kcal)

  • Oven-baked Cauliflower Veggie Tots

    Other intervention

    Oven-baked Cauliflower Veggie Tots (186 g; Green Giant). Test treatments matched for calories (284 kcal)

  • No Side

    Other intervention

    No side control (no caloric contribution).

Treatment groups

30 Participants
are divided into 6 treatment groups

6

Treatment groups

See each treatment group below.

Group A: Oven-baked Home FriesExperimental treatment 1 intervention
Group B: Oven-baked White Russet PotatoExperimental treatment 1 intervention
Group C: Oven-baked FriesExperimental treatment 1 intervention
Group D: Deep Fried, Quick Serve FriesExperimental treatment 1 intervention
Group E: Oven-baked Cauliflower Veggie TotsExperimental treatment 1 intervention
Group F: No SideExperimental treatment 1 intervention

Trial outcomes

Primary outcomes

1

Glycemic Response (Acute Phase)

Blood glucose (mmol/L). Blood glucose concentrations will be measured using a Dexcom G7 CGM system.

Time frame
Change from baseline (measured at baseline (0-minute), 15-minute, 30-minute, 60-minute, 90-minute, and 120-minute post-treatment consumption).
2

Rest-of-day Blood Glucose

Blood glucose (mmol/L). Rest-of-day blood glucose concentrations will be determined using a Dexcom G7 CGM system.

Time frame
Continuous measurements for 24 hours post-treatment consumption.
3

Ad Libitum Food Intake

Lunch pizza meal. Food intake will be determined by weighing the meal before and after serving. The net weight of the test meal will be converted to calories.

Time frame
At 120 minutes post-treatment consumption

Secondary outcomes

1

Subjective Appetite

A visual analogue scale (VAS) with four questions will be administered to assess desire to eat, fullness, hunger, and prospective food consumption. Individual questions will be used to form a composite score. Each VAS will be administered via a digital software application (Express VAS, Toronto, Ontario, Canada) on a Dell tablet where participants will place an 'X" on the VAS line (100 unit scale).

Time frame
Change from baseline (measured at baseline (0-minute), 15-minute, 30-minute, 60-minute, 90-minute, and 120-minute post-treatment consumption).
2

Rest-of-day Food Intake

Participants will be sent home with a rest-of-the-day food intake recall sheet to record their snacks, meals, and beverages. Rest of day food log.

Time frame
For the rest of the day following test session completion (1 day)
3

Subjective Emotions

A visual analogue scale (VAS) with thirteen questions will be administered to assess subjective emotions and mood (aggression, anger, excitement, disappointment, happiness, upset, frustration, alertness, sadness, tension, exhaustion, calmness, and sleepiness). Individual questions will be used to form a composite emotion score. Each VAS will be administered via a digital software application (Express VAS, Toronto, Ontario, Canada) on a Dell tablet where participants will place an 'X" on the VAS line (100 unit scale).

Time frame
Change from baseline (measured at baseline (0-minute), 15-minute, 30-minute, 60-minute, 90-minute, and 120-minute post-treatment consumption).

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Toronto Metropolitan University

Lead sponsor

Alliance for Potato Research and Education

Collaborator

Source ClinicalTrials.gov
Apply now